No Data
Jacobio Pharmaceuticals Group Insider Purchases Yet To Pay Off Regardless Of Recent Strength
Jaccoo-B (01167) will showcase the clinical data of the BET inhibitor JAB-8263 at the 66th American Society of Hematology Annual Meeting in 2024.
Kaska-B (01167) announced that the company will participate in the 66th American Society of Hematology (ASH) in 2024...
JACOBIO-B: 2024 INTERIM REPORT
Jiakangsi-B (01167.HK): The company received the first payment for the exclusive license agreement with shanghai allist pharmaceuticals co., ltd. on GLECIRASIB and JAB-3312, as well as partial compensation for research and development expenses and other p
Grants of September 27th, Akesi-B (01167.HK) announced an exclusive license agreement with shanghai allist pharmaceuticals co., ltd. for Glecirasib and JAB-3312. The Company's subsidiary, Beijing Akesi New Drug Development Co., Ltd. (an indirectly-held non-wholly-owned subsidiary of the Company), has received an amount of approximately RMB 0.173 billion on August 30, 2024 from shanghai allist pharmaceuticals co., ltd. for the external license agreement on KRAS G12C inhibitor Glecirasib (JAB-21822) and SHP2 variant inhibitor JAB-3312, including an initial payment.
Jacobio Pharmaceuticals Group Cancer Drug's IND Application Gets NDMA's Nod
Hong Kong stock anomaly | Juhuasuan-B (01167) rose more than 4% at the end of the day. Pan-KRAS inhibitors approved for clinical trials in the usa.
Jiakuosi-B(01167) rose more than 4% in the final trading session, as of the time of writing, it rose 2.96%, to 1.74 Hong Kong dollars, with a turnover of 4.7074 million Hong Kong dollars.
No Data
No Data
